TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TELA Bio (NASDAQ: TELA) announced that its Compensation Committee has approved inducement grants of restricted stock units (RSUs) to three new employees. The grants, totaling 1,700 shares of common stock, were issued on December 11, 2024. These RSUs will vest in equal annual installments over four years, contingent on continued employment. The grants were made under Nasdaq Rule 5635(c)(4) as part of the employees' compensation packages and to incentivize their acceptance of employment with the company.
TELA Bio (NASDAQ: TELA) ha annunciato che il suo Comitato per le Compensazioni ha approvato concessioni di unità azionarie limitate (RSU) a tre nuovi dipendenti. Le concessioni, per un totale di 1.700 azioni ordinarie, sono state emesse l'11 dicembre 2024. Queste RSU si svincoleranno in rate annuali uguali nel corso di quattro anni, a condizione del continuo impiego. Le concessioni sono state effettuate ai sensi della Regola 5635(c)(4) del Nasdaq come parte dei pacchetti retributivi dei dipendenti e per incentivare l'accettazione dell'impiego con l'azienda.
TELA Bio (NASDAQ: TELA) anunció que su Comité de Compensación ha aprobado concesiones de unidades de acciones restringidas (RSUs) a tres nuevos empleados. Las concesiones, que suman un total de 1,700 acciones ordinarias, se emitieron el 11 de diciembre de 2024. Estas RSUs se liberarán en cuotas anuales iguales durante cuatro años, sujeto a la continuidad del empleo. Las concesiones se realizaron bajo la Regla 5635(c)(4) de Nasdaq como parte de los paquetes de compensación de los empleados y para incentivar su aceptación del empleo con la empresa.
TELA Bio (NASDAQ: TELA)는 보상위원회가 세 명의 새로운 직원에게 제한 주식 단위(RSU) 보상을 승인했다고 발표했습니다. 총 1,700주의 일반 주식이 2024년 12월 11일에 발행되었습니다. 이 RSU는 4년 동안 매년 동일한 분할로 상환됩니다, 고용이 지속되는 조건 하에. 이 보상은 직원의 보상 패키지의 일환으로, Nasdaq 규칙 5635(c)(4)에 따라 이루어졌으며, 직원의 고용 수락을 유도하기 위한 것입니다.
TELA Bio (NASDAQ: TELA) a annoncé que son Comité de Rémunération a approuvé des attributions d'unités d'actions restreintes (RSUs) à trois nouveaux employés. Les attributions, totalisant 1 700 actions ordinaires, ont été émises le 11 décembre 2024. Ces RSUs seront acquises par parts égales sur quatre ans, sous réserve de la poursuite de l'emploi. Les attributions ont été effectuées conformément à la règle 5635(c)(4) de Nasdaq dans le cadre des paquets de rémunération des employés et pour inciter leur acceptation d'un emploi au sein de l'entreprise.
TELA Bio (NASDAQ: TELA) hat bekannt gegeben, dass der Vergütungsausschuss die Gewährung von eingeschränkten Aktieneinheiten (RSUs) an drei neue Mitarbeiter genehmigt hat. Die Gewährungen, die insgesamt 1.700 Stammaktien umfassen, wurden am 11. Dezember 2024 ausgegeben. Diese RSUs werden über einen Zeitraum von vier Jahren in gleichen jährlichen Raten fällig, vorausgesetzt, dass das Beschäftigungsverhältnis fortbesteht. Die Gewährungen wurden gemäß der Nasdaq-Regel 5635(c)(4) als Teil der Vergütungspakete der Mitarbeiter und zur Förderung ihrer Annahme der Anstellung im Unternehmen vorgenommen.
- Successful attraction of new talent with equity compensation
- Minor shareholder dilution from 1,700 new shares
MALVERN, Pa., Dec. 13, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 1,700 shares of its common stock to three newly-hired employees, with a grant date of December 11, 2024 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with TELA Bio.
The restricted stock units will vest in equal annual installments over four years, subject to each individual's continued service with TELA Bio through the applicable vesting dates.
About TELA Bio, Inc.
TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. For more information, visit www.telabio.com.
Caution Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements and reflect the current beliefs of TELA Bio's management. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements. These risks and uncertainties are described more fully in the "Risk Factors" section and elsewhere in our filings with the Securities and Exchange Commission and available at www.sec.gov, including in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Any forward-looking statements that we make in this announcement speak only as of the date of this press release, and TELA Bio assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise after the date of this press release, except as required under applicable law.
Investor Contact
Louisa Smith
ir@telabio.com
FAQ
How many shares were granted in TELA Bio's December 2024 inducement grants?
What is the vesting schedule for TELA Bio's December 2024 RSU grants?
When were TELA Bio's latest inducement grants approved?
Under which Nasdaq rule were TELA Bio's inducement grants issued?
